

Two Diagrams present

Mackenzie 10/1/17

1) Valproic Acid is a short chain fatty acid, used in psychiatric disorders

It Acts on GABA levels in the Brain, Blocks Histone deacetylase inhibitor, and Blocks Voltage gated ion channels.

GABA is formed from  $\alpha$ -KG in the TCA cycle. Valproic Acid inhibits GABA transaminase and succinate semialdehyde dehydrogenase, which degrades GABA

Valproic Acid Also has Anti-epileptic properties By Blocking Voltage gated Sodium &  $Ca^{2+}$  channels, To decreasing the frequency of firing of neurons. It has Also Been shown to inhibit HDAC1 which increases the expression of Apoptosis and anti tumor action.

known VPA is a highly <sup>(87-95%)</sup> Bound protein Resulting in low clearance.

3 Mechanisms for metabolism, Glucuronidation, Beta oxidation in the mitochondria and CYP450 mediated oxidation (this is a minor role however).




The Valproate Glucuronide is the major metabolite 30-50% excreted in the urine.

It also can be brought into the liver via a carnitine shuttle. Then through beta-oxidation it is Broken Down to several metabolites.

A slow hydrolysis by an Acyl CoA thioesterase creates 3-Oxo-VPA which is ~~an end product~~ then used By a thioesterase which turns it into a thiol conjugate

# Pharmacodynamics


Valproic Acid (VPA)



## Cyp 2c9

②

i) It is a phase I drug metabolizing cytochrome P450 enzyme isoform that is primarily expressed in the liver and has the 2nd highest expression of all CYP isoforms. It is responsible for 15-20% of all drugs in the phase I of detoxification. It is known to metabolize Talbutamide to hydroxymethyltalbutamide.



① It starts when Iron<sup>3+</sup> binds to the Iron. The Iron becomes reduced to Fe<sup>2+</sup>.

② O<sub>2</sub> then binds to the enzyme.

③ O<sub>2</sub> is then activated in a 1 electron reduction. A single O<sub>2</sub> atom is dissociated with an oxidation of Iron and protonation of complex involves H<sub>2</sub>O leaving.

The remaining O atom is highly energetic and reacts with substrate, which then leaves.

### 3) Aminoglycosides and Nephrotoxicity.

The Dose and several Days of 10 to 20mg/kg of Body weight is the therapeutic dose. They change the lysosomes of the proximal tubule - this effects the Reabsorption of many minerals such as  $Mg^{2+}$ ,  $Ca^{2+}$ ,  $K^{+}$  and also ~~CAST~~ phospholipids, and glucose in excretion. If continued Dose we occurs then it can lead to Acute Renal failure.

If high Doses of 40mg/kg Are achieved then Cortical necrosis and Renal failure occur rapidly.

While tubular Necrosis is evident the Mechanism of how it happens is unknown though several mechanisms are ~~could~~ potentially be the cause. The Damage is usually repaired After it has been Done, as toxicity is ~~shered~~ rapidly.

As stated it would greatly Decrease the Reabsorption in the proximal tubule leading to Dehydration, polyuria, hypotension, Nausea, Fatigue, weakness. This is because the Blood volume is Decreasing Dramatically and you are losing sugar cells, Blood, and Ions. These are all crucial for function ~~and~~ Due to 90% of Reabsorption occurring at the proximal convoluted tubule it will cause large Disturbances.

It is largely eliminated By glomerular filtration.

- 1) Ghodke-Puranik Yogita, Thorn Caroline F, Lamba Jatinder K, Leeder J Steven, Song Wen, Birnbaum Angela K, Altman Russ B, Klein Teri E. "Valproic acid pathway: pharmacokinetics and pharmacodynamics" *Pharmacogenetics and genomics* (2013)
- 2) Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. *Br J Clin Pharmacol.* 1998;45:525–538.
- 3) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism Miners J O, Birkett D J in *British journal of clinical pharmacology* (1998)
- 4) Marie-Paule Mingeot-Leclercq\* and Paul M. Tulkens Aminoglycosides: Nephrotoxicity *Antimicrob. Agents Chemother.* May 1999 vol. 43 no. 5 1003-1012
- 5) Guengerich F P, *Humancytochromes P450*. In: Ortiz de Montellano PR, editor. *Cytochrome P450, structure, mechanism and biochemistry* (3rd Ed.). New York, Kluwer/Plenum Press, 2005. p. 377– 530.